Merck KGaA has failed to block Pfizer’s ‘Abrysvo’ trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities.
For information on rights and reprints, contact subscriptions@lawyerly.com.au